Axsome Therapeutics Completes U.S. Acquisition of Sunosi® (solriamfetol) for Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea
- Monday, May 9, 2022, 7:00
- Finance
- Add a comment
Axsome is committed to providing patients uninterrupted access to Sunosi and advancing research for patients living with sleep disorders Insurance coverage for Sunosi totals 96% of commercial lives or approximately 253 million lives across all channels Comprehensive patient assistance…
About the Author
adminasapcorp has written 41558 stories on this site.